MX366765B - Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. - Google Patents

Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.

Info

Publication number
MX366765B
MX366765B MX2015009818A MX2015009818A MX366765B MX 366765 B MX366765 B MX 366765B MX 2015009818 A MX2015009818 A MX 2015009818A MX 2015009818 A MX2015009818 A MX 2015009818A MX 366765 B MX366765 B MX 366765B
Authority
MX
Mexico
Prior art keywords
ppar
agonists
treatment
multiple sclerosis
int131
Prior art date
Application number
MX2015009818A
Other languages
English (en)
Other versions
MX2015009818A (es
Inventor
David Weinstein
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of MX2015009818A publication Critical patent/MX2015009818A/es
Publication of MX366765B publication Critical patent/MX366765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Métodos para tratar esclerosis múltiple (EM) con agonistas de PPAR?, y en particular, con el compuesto de fórmula (I) conocido como INT131: (ver Fórmula).
MX2015009818A 2013-01-30 2014-01-23 Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. MX366765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758641P 2013-01-30 2013-01-30
PCT/US2014/012656 WO2014120538A1 (en) 2013-01-30 2014-01-23 PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS

Publications (2)

Publication Number Publication Date
MX2015009818A MX2015009818A (es) 2015-10-29
MX366765B true MX366765B (es) 2019-07-23

Family

ID=51223587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009818A MX366765B (es) 2013-01-30 2014-01-23 Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.

Country Status (15)

Country Link
US (3) US9061020B2 (es)
EP (1) EP2950798B1 (es)
JP (3) JP5989921B2 (es)
KR (2) KR102056756B1 (es)
CN (1) CN105228622B (es)
AU (1) AU2014212740B2 (es)
BR (1) BR112015018048A2 (es)
CA (1) CA2899187C (es)
EA (2) EA201792096A3 (es)
ES (1) ES2883141T3 (es)
HK (1) HK1218510A1 (es)
IL (2) IL240051A (es)
MX (1) MX366765B (es)
SG (2) SG11201505944QA (es)
WO (1) WO2014120538A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
ES2883141T3 (es) * 2013-01-30 2021-12-07 Intekrin Therapeutics Inc Agonista de PPAR-gamma para el tratamiento de la esclerosis múltiple
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
KR20190064573A (ko) * 2016-08-18 2019-06-10 인테크린 테라퓨틱스, 아이엔씨. 혈액 암 치료용 PPARγ 작용제
CA3033971A1 (en) * 2016-08-18 2018-02-22 Intekrin Therapeutics, Inc. Ppar.gamma. agonist for treatment of bone disorders
AU2017326261A1 (en) * 2016-09-13 2019-04-04 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with CHS-131
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
WO2005086904A2 (en) * 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
WO2009007673A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
EP2242747A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
ES2883141T3 (es) * 2013-01-30 2021-12-07 Intekrin Therapeutics Inc Agonista de PPAR-gamma para el tratamiento de la esclerosis múltiple

Also Published As

Publication number Publication date
JP6466540B2 (ja) 2019-02-06
IL240051A (en) 2016-11-30
EA201792096A2 (ru) 2018-01-31
SG11201505944QA (en) 2015-08-28
US20150238478A1 (en) 2015-08-27
EA201591399A1 (ru) 2015-12-30
CN105228622B (zh) 2017-09-22
EA201792096A3 (ru) 2018-05-31
US20140213612A1 (en) 2014-07-31
CA2899187A1 (en) 2014-08-07
KR20160137653A (ko) 2016-11-30
JP2017014251A (ja) 2017-01-19
HK1218510A1 (zh) 2017-02-24
EP2950798A4 (en) 2016-06-29
EP2950798B1 (en) 2021-05-12
SG10201805896SA (en) 2018-08-30
BR112015018048A2 (pt) 2020-01-28
US20170143687A1 (en) 2017-05-25
AU2014212740A1 (en) 2015-08-13
IL248594A0 (en) 2016-12-29
US9867816B2 (en) 2018-01-16
EA029216B1 (ru) 2018-02-28
IL240051A0 (en) 2015-09-24
KR102056756B1 (ko) 2019-12-17
US9539249B2 (en) 2017-01-10
WO2014120538A1 (en) 2014-08-07
AU2014212740B2 (en) 2015-12-24
IL248594B (en) 2021-10-31
CA2899187C (en) 2016-06-07
JP6224189B2 (ja) 2017-11-01
KR20150133182A (ko) 2015-11-27
US9061020B2 (en) 2015-06-23
JP2016506956A (ja) 2016-03-07
ES2883141T3 (es) 2021-12-07
MX2015009818A (es) 2015-10-29
CN105228622A (zh) 2016-01-06
JP5989921B2 (ja) 2016-09-07
EP2950798A1 (en) 2015-12-09
JP2018039817A (ja) 2018-03-15

Similar Documents

Publication Publication Date Title
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12015502659A1 (en) Surface treatment compositions comprising photochromic dyes
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2020002544A (es) Sales de glicopirrolato.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX369290B (es) Inhibidores de fbx03.
EA201591709A1 (ru) 5-бром-индирубины
WO2014146111A3 (en) Analgesic compounds and methods of use
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
MX2016005219A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол
UA86158U (en) Antibacterial agent
MX2016005221A (es) Tinturas acidas, proceso para su produccion y su uso.
UA86107U (ru) Пиперазиния 1-н-бутилтеобромин-8-илтиоацетат, который проявляет диуретическое действие
UA80877U (en) 2-hydroxyethyl-1,3,4-trimethylcyclohex-3-ene-1-carboxylate
UA91089U (uk) Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства

Legal Events

Date Code Title Description
FG Grant or registration